Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GZR102 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.

Zhitongcaijing · 05/16 08:25
Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that the GZR102 injection independently developed by the company is undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject.